The outbreak could have an impact on the company’s manufacturing, supply chain and clinical trial operations, Pfizer said under the risk factors section of a regulatory filing. The outbreak that began in Wuhan at the end of last year has killed over 2,700 in China, with over 78,000 confirmed cases of infection, and has now spread to several other countries. Merck & Co on Wednesday said the outbreak has negatively affected some of its clinical trials and has seen a limited effect on its supply chain of drugs into and raw materials out of China. …read more
Source:: Yahoo Finance
